Related Experiment Video
Updated: Sep 13, 2025
The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice
Published on: October 24, 2018
Efficacy of Pediococcus acidilactici CCFM6432 in alleviating anhedonia in major depressive disorder: A randomized
Du-Xing Li1, Qi-Ming Hu2, Chen-Chen Xu2
1Department of Psychiatry, The Affiliated Mental Health Center of Jiangnan University, Wuxi 214151, Jiangsu Province, China.
Background:
Anhedonia, a hallmark symptom of major depressive disorder (MDD), is often resistant to common antidepressants. Preliminary evidence indicates that Pediococcus acidilactici (P. acidilactici) CCFM6432 may offer potential benefits in ameliorating this symptomatology in patients with MDD.
Aim:
To further assess the efficacy of P. acidilactici CCFM6432 in alleviating anhedonia in patients with MDD, using a combination of objective and subjective assessment tools.
Methods:
Adult patients with MDD exhibiting anhedonic symptoms were enrolled and randomly assigned to two treatment groups: One receiving standard antidepressant therapy plus P. acidilactici CCFM6432, and the other receiving standard antidepressant treatment along with a placebo, for 30 days. Assessments were conducted at baseline and post-intervention using the Hamilton Depression Rating Scale (HAMD), Temporal Experience of Pleasure Scale (TEPS), and synchronous electroencephalography (EEG) during a "Doors Guessing Task." Changes in both clinical outcomes and EEG biomarkers, specifically the stimulus-preceding negativity (SPN) and feedback-related negativity amplitudes, were analyzed.
Results:
Of the 92 screened participants, 71 were enrolled and 55 completed the study (CCFM6432 group: n = 27; Placebo group: n = 28). No baseline differences were noted between the groups in terms of demographics, clinical assessments, or EEG metrics. A mixed-design analysis of variance revealed that the CCFM6432 group showed significantly greater improvements in both HAMD and TEPS scores compared to the Placebo group. Moreover, the CCFM6432 group demonstrated a significant increase in SPN amplitudes, which were inversely correlated with the improvements observed in HAMD scores. No such changes were observed in the Placebo group.
Conclusion:
Adjunctive administration of P. acidilactici CCFM6432 not only augments the therapeutic efficacy of antidepressants but also significantly ameliorates the symptoms of anhedonia in MDD.
Insights
Pediococcus acidilactici CCFM6432 supplementation improved anhedonia symptoms in major depressive disorder (MDD) patients. This probiotic enhanced antidepressant efficacy and showed positive changes in EEG biomarkers, suggesting a novel therapeutic avenue.
Area of Science:
- Neuroscience
- Microbiology
- Psychiatry
Background:
- Anhedonia is a core symptom of major depressive disorder (MDD) often unresponsive to standard treatments.
- Preliminary research suggests Pediococcus acidilactici CCFM6432 may alleviate anhedonia in MDD patients.
Purpose of the Study:
- To evaluate the efficacy of Pediococcus acidilactici CCFM6432 in reducing anhedonia in MDD patients.
- To assess the impact of this probiotic on both clinical and electroencephalography (EEG) markers of anhedonia.
Main Methods:
- A 30-day randomized controlled trial involving MDD patients with anhedonia.
- Participants received standard antidepressants plus either Pediococcus acidilactici CCFM6432 or a placebo.
- Clinical assessments (HAMD, TEPS) and EEG (SPN, FRN amplitudes) were performed at baseline and post-intervention.
Main Results:
- The Pediococcus acidilactici CCFM6432 group showed significant improvements in HAMD and TEPS scores compared to placebo.
- EEG analysis revealed increased SPN amplitudes in the probiotic group, correlating with reduced depressive symptoms.
- No significant changes in EEG biomarkers were observed in the placebo group.
Conclusions:
- Adjunctive Pediococcus acidilactici CCFM6432 enhances antidepressant therapy for MDD.
- This probiotic effectively ameliorates anhedonia symptoms in MDD patients.
- Pediococcus acidilactici CCFM6432 demonstrates potential as a novel therapeutic agent for anhedonia.
More Related Videos
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
01:25Antidepressant Drugs: Overview
01:27Depressive Disorders: MDD and Dysthymia
01:05Long-term Depression